QRxPharma has executed its License and Option Agreement (LOA) with Actavis, finalizing the terms and conditions to commercialize MoxDuo IR in the U.S. for acute pain. In December 2011, the companies signed a letter of intent secured by a $6 million non-refundable upfront signing fee to QRxPharma. “Actavis is proving to be an exceptional partner. The strategic synergies between our companies and our collaboration at the joint steering committee level are critical success factors going forward,” ...